• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cancer Pain - Pipeline Review, H1 2012 Product Image

Cancer Pain - Pipeline Review, H1 2012

  • ID: 2092638
  • March 2012
  • 135 pages
  • Global Markets Direct

Cancer Pain – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Cancer Pain - Pipeline Review, H1 2012', provides an overview of the Cancer Pain therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. 'Cancer Pain - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cancer Pain.
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Cancer Pain
Cancer Pain Therapeutics under Development by Companies
Cancer Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Cancer Pain Therapeutics – Products under Development by Companies
Cancer Pain Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Cancer Pain Therapeutics Development
Johnson & Johnson
Sanofi-Aventis
BioDelivery Sciences International, Inc.
Ipsen S.A.
Aphios Corporation
AcelRx Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Nippon Kayaku Co., Ltd.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Taiho Pharmaceutical Co., Ltd.
GW Pharmaceuticals plc
IntelGenx Technologies Corp.
Benitec Ltd.
NovaDel Pharma, Inc.
Diamyd Medical AB
ProStrakan Group plc
Orexo AB
BioAlliance Pharma SA
Labtec GmbH
Immupharma Plc
Phosphagenics Limited
WEX Pharmaceuticals Inc.
QRxPharma Limited
APEIRON Biologics AG
Xenome Ltd.
Winston Pharmaceuticals, Inc.
RaQualia Pharma Inc.
Cancer Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PF-4383119 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR411298 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVD-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIM 46187 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fentanyl Lauriad - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Delta 9-THC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Delta 9-THCA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nucynta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abstral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relivar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPM Oxycodone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONSOLIS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tectin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OVF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MoxDuo CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42160443 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tylenol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xen2174 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufentanil Transdermal System - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydromorphone Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Resiniferatoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPP-102199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fentanyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TK-642 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKQ-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OX27 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civamide Sterile Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DEX-IN - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THA901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ddRNAi Program For Cancer-Associated Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APN601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNSB004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cancer Pain Therapeutics – Drug Profile Updates
Cancer Pain Therapeutics – Discontinued Products
Cancer Pain Therapeutics - Dormant Products
Cancer Pain – Product Development Milestones
Featured News & Press Releases
Feb 15, 2012: Phosphagenics Delivers Further Positive Oxycodone Patch Trial Results
Feb 07, 2012: Almirall Starts New Wave Of Regulatory Submissions For Sativex In Europe
Dec 30, 2011: FDA Approves Shared REMS Program For All TIRF Pain Treatments
Dec 29, 2011: BioDelivery Sciences Announces ONSOLIS To Benefit From Approval Of Class-Wide REMS For All Transmucosal Fentanyl Products
Dec 20, 2011: Orexo Announces Positive Study Results For OX27
Nov 07, 2011: TTY Biopharm Submits Marketing Authorization For BEMA Fentanyl In Taiwan
Aug 22, 2011: BioDelivery Sciences Announces Commercial Launch Of ONSOLIS In Canada
Jul 21, 2011: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy For FENTORA And ACTIQ
Jun 30, 2011: GW Pharmaceuticals Announces Initiation Of Second Phase III Sativex Clinical Trial
Jun 14, 2011: Paladin Labs Announces Canadian Launch Of Abstral
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cancer Pain, H1 2012
Products under Development for Cancer Pain – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012
Johnson & Johnson, H1 2012
Sanofi-Aventis, H1 2012
BioDelivery Sciences International, Inc., H1 2012
Ipsen S.A., H1 2012
Aphios Corporation, H1 2012
AcelRx Pharmaceuticals, Inc., H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Nippon Kayaku Co., Ltd., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Taiho Pharmaceutical Co., Ltd., H1 2012
GW Pharmaceuticals plc, H1 2012
IntelGenx Technologies Corp., H1 2012
Benitec Ltd., H1 2012
NovaDel Pharma, Inc., H1 2012
Diamyd Medical AB, H1 2012
ProStrakan Group plc, H1 2012
Orexo AB, H1 2012
BioAlliance Pharma SA, H1 2012
Labtec GmbH, H1 2012
Immupharma Plc, H1 2012
Phosphagenics Limited, H1 2012
WEX Pharmaceuticals Inc., H1 2012
QRxPharma Limited, H1 2012
APEIRON Biologics AG, H1 2012
Xenome Ltd., H1 2012
Winston Pharmaceuticals, Inc., H1 2012
RaQualia Pharma Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Cancer Pain Therapeutics – Drug Profile Updates
Cancer Pain Therapeutics – Discontinued Products
Cancer Pain Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Cancer Pain, H1 2012
Products under Development for Cancer Pain – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos